PMID- 23348902
OWN - NLM
STAT- MEDLINE
DCOM- 20140113
LR  - 20230210
IS  - 1530-0285 (Electronic)
IS  - 0893-3952 (Print)
IS  - 0893-3952 (Linking)
VI  - 26
IP  - 6
DP  - 2013 Jun
TI  - Novel dual-color immunohistochemical methods for detecting ERG-PTEN and 
      ERG-SPINK1 status in prostate carcinoma.
PG  - 835-48
LID - 10.1038/modpathol.2012.234 [doi]
AB  - Identification of new molecular markers has led to the molecular classification 
      of prostate cancer based on driving genetic lesions. The translation of these 
      discoveries for clinical use necessitates the development of simple, reliable and 
      rapid detection systems to screen patients for specific molecular aberrations. We 
      developed two dual-color immunohistochemistry-based assays for the simultaneous 
      assessment of ERG-PTEN and ERG-SPINK1 in prostate cancer. A total of 232 cases 
      from 184 localized and 48 metastatic prostate cancers were evaluated for ERG-PTEN 
      and 284 cases from 228 localized and 56 metastatic prostate cancers were 
      evaluated for ERG-SPINK1. Of the 232 cases evaluated for ERG-PTEN, 81 (35%) 
      ERG-positive and 77 (33%) PTEN-deleted cases were identified. Of the 81 
      ERG-positive cases, PTEN loss was confirmed in 35 (15%) cases by fluorescence in 
      situ hybridization (FISH). PTEN status was concordant in 203 cases (sensitivity 
      90% and specificity 87%; P<0.0001) by both immunohistochemisty and FISH; however, 
      immunohistochemisty could not distinguish between heterozygous and homozygous 
      deletion status of PTEN. Of the 284 cases evaluated for ERG-SPINK1, 111 (39%) 
      cases were positive for ERG. In the remaining 173 ERG-negative cases, SPINK1 was 
      positive in 26 (9%) cases. SPINK1 expression was found to be mutually exclusive 
      with ERG expression; however, we identified two cases, of which one showed 
      concomitant expression of ERG and SPINK1 in the same tumor foci, and in the 
      second case ERG and SPINK1 were seen in two independent foci of the same tumor 
      nodule. Unlike the homogenous ERG staining in cancer tissues, heterogeneous 
      SPINK1 staining was observed in the majority of the cases. Further studies are 
      required to understand the molecular heterogeneity of cases with concomitant 
      ERG-SPINK1 expression. Automated dual ERG-PTEN and ERG-SPINK1 immunohistochemisty 
      assays are simple, reliable and portable across study sites for the simultaneous 
      assessment of these proteins in prostate cancer.
FAU - Bhalla, Ritu
AU  - Bhalla R
AD  - Michigan Center for Translational Pathology, Ann Arbor, MI, USA.
FAU - Kunju, Lakshmi P
AU  - Kunju LP
FAU - Tomlins, Scott A
AU  - Tomlins SA
FAU - Christopherson, Kelly
AU  - Christopherson K
FAU - Cortez, Connie
AU  - Cortez C
FAU - Carskadon, Shannon
AU  - Carskadon S
FAU - Siddiqui, Javed
AU  - Siddiqui J
FAU - Park, Kyung
AU  - Park K
FAU - Mosquera, Juan Miguel
AU  - Mosquera JM
FAU - Pestano, Gary A
AU  - Pestano GA
FAU - Rubin, Mark A
AU  - Rubin MA
FAU - Chinnaiyan, Arul M
AU  - Chinnaiyan AM
FAU - Palanisamy, Nallasivam
AU  - Palanisamy N
LA  - eng
GR  - P50 CA69568/CA/NCI NIH HHS/United States
GR  - U01 CA113913/CA/NCI NIH HHS/United States
GR  - P50 CA069568/CA/NCI NIH HHS/United States
GR  - U01 CA111275/CA/NCI NIH HHS/United States
GR  - HHMI/Howard Hughes Medical Institute/United States
GR  - R01 CA132874/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130125
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Carrier Proteins)
RN  - 0 (ERG protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (SPINK1 protein, human)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcriptional Regulator ERG)
RN  - 50936-63-5 (Trypsin Inhibitor, Kazal Pancreatic)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (PTEN protein, human)
SB  - IM
MH  - Biomarkers, Tumor/*analysis/genetics
MH  - Carcinoma/*chemistry/secondary
MH  - Carrier Proteins/*analysis
MH  - Gene Deletion
MH  - Heterozygote
MH  - Homozygote
MH  - Humans
MH  - *Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Oncogene Proteins, Fusion/*analysis/genetics
MH  - PTEN Phosphohydrolase/*analysis/genetics
MH  - Predictive Value of Tests
MH  - Prostatic Neoplasms/*chemistry/genetics/pathology
MH  - Tissue Array Analysis
MH  - Trans-Activators/*analysis
MH  - Transcriptional Regulator ERG
MH  - Trypsin Inhibitor, Kazal Pancreatic
PMC - PMC3672354
MID - NIHMS426248
EDAT- 2013/01/26 06:00
MHDA- 2014/01/15 06:00
PMCR- 2013/12/01
CRDT- 2013/01/26 06:00
PHST- 2013/01/26 06:00 [entrez]
PHST- 2013/01/26 06:00 [pubmed]
PHST- 2014/01/15 06:00 [medline]
PHST- 2013/12/01 00:00 [pmc-release]
AID - S0893-3952(22)03081-2 [pii]
AID - 10.1038/modpathol.2012.234 [doi]
PST - ppublish
SO  - Mod Pathol. 2013 Jun;26(6):835-48. doi: 10.1038/modpathol.2012.234. Epub 2013 Jan 
      25.